Drug Trial Radar · NCT04683185
A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Jul 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Dec 28, 2020
Primary completion
Jun 21, 2021
Study completion Jun 21, 2021
Sponsor
- Lead sponsor
- Eisai Co., Ltd.Eisai
- Sponsor type
- Industry
- First posted
- Dec 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple ascending oral doses of E6742 in Japanese healthy adult participants.
Conditions
- Healthy Volunteers
Interventions
E6742Drug
E6742 tablets.
PlaceboDrug
E6742-matched placebo tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to 28 days after the last dose of study drug (approximately Day 35)
- Cmax: Maximum Observed Plasma Concentration for E6742 and its Metabolite (ER-001132963) on Day 1Time frame: Day 1: 0-12 hours
- tmax: Time at Which the Highest Drug Plasma Concentration Occurs for E6742 and its Metabolite (ER-001132963) on Day 1Time frame: Day 1: 0-12 hours
- AUC(0-12h): Area Under the Plasma Concentration-time Curve From Zero Time to 12 Hours Postdose for E6742 and its Metabolite (ER-001132963) on Day 1Time frame: Day 1: 0-12 hours
- AUC Metabolite to E6742 Ratio Following Molecular Weight Correction to E6742 Equivalents on Day 1Time frame: Day 1: 0-12 hours
- Css,max: Maximum Observed Plasma Concentration at Steady State for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-168 hours
- tss,max: Time at Which the Highest Drug Plasma Concentration Occurs at Steady State for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-168 hours
- Css,av: Average Steady State Plasma Concentration for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-168 hours
- AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to Time of Last Quantifiable Concentration for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-168 hours
- AUC(0-12hr): Area Under the Plasma Concentration-time Curve Within a Dosing Interval at Steady State for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-12 hours
- t1/2: Terminal Elimination Phase Half-life for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-168 hours
- CLss/F: Apparent Total Clearance at Steady State for E6742 on Day 7Time frame: Day 7: 0-168 hours
- Vss/F: Apparent Volume of Distribution at Steady State for E6742 on Day 7Time frame: Day 7: 0-168 hours
- PTF: Peak-trough Fluctuation for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-168 hours
- Accumulation Ratio for Cmax and AUC for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-168 hours
- Metabolite to E6742 AUC Ratio Following Molecular Weight Correction to E6742 Equivalents on Day 7Time frame: Day 7: 0-168 hours
- AUC(0-12hr)ss: Area Under the Plasma Concentration-time Curve Within a Dosing Interval at Steady State for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-12 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eisai Trial Site #1
Bunkyō-Ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.